Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
NCT02852837Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability, Maximum Observed Plasma Concentration and 5 more. Started Sep 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02852837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852837.